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Inhibitors of myosin light chain kinase. 1-~5-chloronaphthalene-l-sulfonyl)-lH-hexahydro-l,4-diazepine hydrochloride (ML-9) and I-(Siodonaph- 
thalene-l-sulfonyl)-l Whexahydro-I ,4-diazepine hydrochloride (ML-7), induced Nitroblue tetrazolium reducing activity, lysozyme activity and mor- 
phological maturation of human monoblastic U937, THP-I and promyelocytic HL-60 cells, but not of erythroblastlc K562 cells. However, three 
analogs of ML-9, which are an inhibitor and an activator of protein kinase C, and a calmodulin antagonist, respectively, did not induce differentia- 
tion of the cells. 
Differentiation; Myosin light chain kinase: ML-9: ML-7: Leukemia cell; U937 cell: HL-60 cell 
1. INTRODUCTION 
Protein kinase activities are important in the regula- 
tion of biological activities of cells such as proliferation 
and differentiation [ 1,2]. Extracellular signals are 
translated into intracellular messenger systems through 
tyrosine protein kinase, phosphatidylinositol turnover 
and GTP binding protein [3]. Activation of phospha- 
tidylinositol turnover increases the level of diacylgly- 
cerol, which is an activator of protein kinase C (PKC), 
and of inositol tr~phosphates, which increase the in- 
tracellular Ca’+ level [3,4]. This Ca” then binds to 
calmodulin and the Cal+-calmodulin complex activates 
further enzymes such as myosin light chain kinase 
(MLCK) [5,6]. PKC and MLCK are serine/threonine 
protein kinases [2]. 
Inhibitors of these signal transduction pathways are 
very useful in studies on the mechanisms of cellular 
growth and differentiation. Herbimycin A, an inhibitor 
of protein tyrosine kinase, induced differentiation of 
human erythroleukemic K562 cells, which have high 
tyrosine kinase activity of p210h”-‘“h’ protein [7], and 
methyl 2,S_dihydroxycinamate, another inhibitor of 
protein tyrosine kinase, enhanced the differentiation of 
Ahhreviafions: PKC, protein kinabe C: MLCK. myoiin light chain 
kinase; ML-Y, l-(~-chloronaphthalenc-I-~ttIfong.l)-lH-he~ahydro- 
I,.&diarepine hydrochloride; Ml.-7, I -(5-iodonapthalene-I-\ul~on!l)- 
IH-hc*ahydro-l,4-diarepine hydrochloride; H-7, I-(5-i\oquinolinc- 
iult’onyl).2-metllylpiperarinc dihydrochloride; W-9, ,V-(6.phenyl- 
hcxyl)-‘-chloro-I-naphtalencsulfonamide; \2’-7, N-(6-aminohcxyl)-5- 
chloro-1-naphthalcne,ulfonalnide; NBT, Nitroblue tctralolium 
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human myeloblastic ML-l cells induced by vitamin Dr 
181. An inhibitor of phosphatidylinositol turnover, 
psi-tectorigenin, and phorbol esters, which are ac- 
tivators of PKC, also induced the differentiation of 
human leukemia cells [8,9]. Therefore, in this study, we 
examined the effects of various inhibitors of protein 
kinases on growth and differentiation of human 
myeloid leukemia cell lines, and found that inhibitors 
of MLCK induced functional and morphological dif- 
ferentiation of some cell lines. 
2. MATERIALS AND METHODS 
2. 1 :\~urerini.~ 
I-(5-Clrloronaphthalene-l-~nIfo~~~!)-IH-he~ah~dro-1,4-dia/epine 
hydrochloride (\!I.-Y), 1~(5-iodonaphthalcIlc-I-,itlfon);l)-I H-hexa- 
hydra-I .4diazepine hydrochloride (hlL-7). I-(5-isoquinolinc\ul- 
fon?‘l)-2-metIrylpipet-arinc dihqdrochloride (H-7), ~~‘-(6-pllenqlhe\~l)- 
‘-chloro--1~naphthalenesulfonamide (X-9) and :C’-(6.arninohe~~l). 
~-cliloro-I-naphthalenezulfonarnide (M’-7) \\crc purcha\etl i’rotn 
Seikngaku Kogyo, Tokyo. Stock tolutionc wert‘ prepared in dimethyl 
\ulfo\ide and diluted with ethanol before use. The final concentration 
of dimethyl wlfo\idc did not eweed O.l”‘o (\!v). 
suspensions of cells (10’ cells/ml) in 2. ml of culture medium \vet-c 
cultured with or without lest compounds in multidishcr (Costar, 
Cambridge, MA) for 5 days. Then cell numbers were counted in a 
Xlodel Ztl Coulter Counter (Coultcr Electronics, L.uton, UK). 
Nitrohlue tcrrazolium (NEST) reduction was atzayed colot-imrlrically 
a\ rcp<)rtCd prcxiously [lj]. Washed cell\ were \onic:ated for 10 5 in a 
cell disruptor (Ultrasonic\, NY) and theit cytosolic iysor)_me activities 
t\err determined by a Iysoplate method [16]. Eryihroid differ-wtiation 
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\\a\ tcored by benzidine staining [17]. Ccl1 morpholog! was evamined 
in cell smears stained ~irh Maq’-C;ruen~ald-Giemaa stain. Naphthol 
AS-D chloroacetate esterax and wnaphrhol acetate esterase wre 
determined cqtochemically with an ectet-ase kit (Sigma Chemical Co.. 
Cr. LOlli\). 
3. RESULTS 
Human monoblastic leukemia U937 cells were 
cultured with various concentrations of ML-9, a potent 
inhibitor of MLCK [18,19]. ML-9 inhibited prolifera- 
tion of the cells, its concentration for 50% inhibition of 
gro\vth (ICYSO) being 21 @I, and induced NBT reducing 
activity concentration-dependently (Fig. la). ML-7, 
another inhibitor of MLCK [19], also induced NBT 
reducing activity. H-7 and SC-9 are an inhibitor and an 
activator of PKC, respectively, and have structures 
similar to ML-9 and ML-7 [20,21]. However, neither 
H-7 nor SC-9 induced NBT reducing activity of the 
cells. Although W-7 is a calmodulin inhibitor with 
structural similarity to ML-9 and inhibits MLCK in- 
directly [22], it did not induce NBT reducing activity of 
U937 cells. The IC~O concentrations of ML-7, H-7, 
SC-9 and W-7 were 25 PM, 30 PM, 20 PM and 15 PM, 
respectively (data not shown). The lysozyme activity of 
U937 cells was also increased by treatment with ML-9 
and ML-7, but not H-7, SC-9 or W-7 (Fig. 1 b). On 
treatment with ML-9 or ML-7 for 7 days, monoblastic 
U937 cells differentiated into monocytic ceils with in- 
creased activities of both naphthol AS-D chloroacetate 
esterase and a-naphthol acetate esterase (data not 
shown). 
Next, we investigated the effect of ML-9 on the dif- 
ferentiation of other human leukemia ceil lines. THP-1 
and HL-60 cells are monoblastic and promyelocytic 
cells, respectively [I 1,121, and have been reported to 
differentiate on treatment with various inducers of dif- 
la 
Concentration (oM 1 
+--e--c 
Concentration (PM) 
l-ig. I. L-ffectr of inhibitor5 of !4LCK and related compound\ ou in- 
duction of NUT reducing activity (a) and Iytotyme activity (b) 01 
UY37 cell,. The cell5 were treated ibith various concentrations of 
\I1 -9 (‘)), ML -7 (0). H-7 (A), SC-Y (A) 01 L\‘-7 (0) for 5 days. 
Values are mean5 i SD for three wparate experiments. 
Table I 
Effects of hll -Y on gl-oath and differentiation of wcral human 
leukemia ceII line< 
CCll5 Growth inhibition NUT reduction? I ywt~me activlrq ’ 
ICq,’ ({IXl) (tario) (ratio) 
IJY37 21 3.0 1.8 
-I-HP-I 29 7.i 4.2 
HL-60 8 1.3 I.5 
K562 8 I.1 UD 
HEL I4 2.0 ND 
“IC’~~,, concentration of \lL-Y required for Wb inhibition of cell 
growth in 5 da)<. 
“Cell, \+crc‘cultured with the IC s,) concentration of IIL-Y fol- 5 dais. 
The NBl‘reducing acti\itie\ of untreated UY37, THP-I. HI:60. K562 
and HEL cell\ were I. 16 t 0. 14. 0.48 t 0.06. 0.7X rt (1.01. I .35 ‘_ 0.15 
and I .04 -c O.OY .,I c,,o 10. cell\, re$pectl\el\. The Iywry~ne acti\ ities of 
untreated 11937, I HP-I and HL-60 cell\ were 2.OtO.3, 6.1 i 0.5 and 
33.Oi IO.2 I! IO” cell\, le\pccti\ely. 
‘ND, not determined. 
ferentiation [9]. ML-9 induced NBT reducing and 
lysozyme activities in THP-1 cells as \vell as U937 cells 
(Table I). ML-9 enhanced the lysozyme activity of 
HL-60 cells only slightly, but it induced morphological 
differentiation of the cells into metamyelocyte-like cells 
(data not sholvn). HEL and K562 cells are 
erythroblastic cells and differentiate into erythrocytic 
or myelomonocytic cells on treatment with inducers 
[9,23]. ML-9 did not augment hemoglobin synthesis in 
HEL or K562 cells (data not shown), but induced NBT 
reducing activity in HEL cells (Table I). 
4. DISCUSSION 
ML-9 has been reported to inhibit MLCK selectively 
with a K, value of 3.8 FM and to affect the biological 
functions of platelets and smooth muscle cells [18,19]. 
HoLvever, there is no report on the relation of MLCK 
activity with cellular differentiation. Therefore, we ex- 
amined the effect of ML-9 on differentiation of human 
leukemia cells. ML-9 induced differentiation of U937 
and other leukemia cells, and another MLCK inhibitor, 
ML-7, also did. PKC is reported to phosphorylate 
myosin light chain by a different mechanism from that 
of MLCK [24]. Therefore, we examined the effect of 
H-7, which is structurally related to ML-9 and inhibits 
PKC [20]. However, H-7 did not induce differentiation 
of the U937 cells, although it induced differentation of 
mouse megakaryoblastic Cl cells [25]. X-9, which is 
also structurally related to ML-9. is an activator of PKC 
[21]. SC-9 did not induce cell differentiation, whereas 
phorbol esters, which are also activators of PKC, are 
known to be potent inducers of differentiation of 
human leukemia cells such as HL-60 and U937 191. The 
Cal+-calmodulin complex activates MLCK and W-7, a 
calmodulin antagonist, inhibits MLCK indirectly [22], 
but it did not induce differentiation of U937 cells. This 
may be due to a difference in types of MLCKs, 
176 
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ca~modu~in-dependent and indepcnd~nt types [6], 
although other possibilities cannot be ruled out. 
U937 cells were reported to differentiate by genistein, 
an inhibitor of protein tyrosine kinase and 
phosphatidylinositol turnover, and psi-tectorigenin [8], 
but not by herbimycin A [7], methyl 2,5-dihydroxycina- 
mate [8], staurosporin, sphingosine or A-3 (data not 
shown). Staurosporin and sphingosine inhibit PKC as 
well as H-7 [26,27] and A-3 inhibits cyclic nucleoside- 
dependent protein kinase, one of the serine/threonine 
kinases f28]. In this study we showed that inhibitors of 
iMLCK induced the differentiation of U937 cells, and 
these resuits suggest that differentiation of human 
leukemia cells is associated with inhibition of MLCK as 
well as inhibition of tyrosine protein kinase and 
phosphatidylinositol turnover. Further studies are in 
progress to elucidate the association of the tyrosine and 
serine/threonine kinase activities with cellular differen- 
tiation more precisely. 
Acknow/rdge,ne,?ts: This work was supported in part by Cirants-in- 
Aid for Cancer Research l’rom the Ministry of Education, Science and 
Culture of Japan, and a grant from rhe Ministry of Health and 
Welfare for a Comprehensive IO-Year Strategy for Cancer Cnnti-ol, 
Japan. 
REFERENCES 
[l] Hunter, T. and Cooper, J.A. (1985) Annu. Rev. Rio&em. 54, 
897-930. 
[2] Edelman, A.M., Blumenthal, D.K. and Krebr, E.G. (1987) An- 
nu. Rev. Biochem. 56, 567-613. 
[3] Nishizuka, Y. (1984) Nature 308, 693-698. 
[4] Berridge, M.J. and Irvine, R.F. (1984) Nature 312, 315-321. 
[5] Klee, C.B., Crouch, T.H. and Richman. P.G. (1980) Annu. 
Rev. Biochem. 4Y, 489-515. 
[6] Ad&rein, R.S. and Eisenberg, E. (1980) Annu. Rev. Biochem. 
49, 921-956. 
[7] Honma, Y., Okabe-Kado, J., Hozumi, M., Uehara, Y. and 
Mizuno, S. (1989) Cancer Res. 49, 331-334. 
@I 
191 
1101 
[l II 
[I21 
[I?1 
[I4 
II-51 
1161 
I171 
11x1 
[I’)1 
[X] 
I211 
1221 
1231 
1241 
WI 
WI 
~271 
1281 
~lakishima, M., Honma, Y ., HoLumi, M., Sampi, K., Hattori. 
M., Umezawa, K. and Mntoyoshi, K. (1991) Leuk. Rw., in 
prcsr. 
Holurni. M. (1983) Adv. Cancer Res. 38, 121-169. 
Sundstrom, C. and Nilsson, K. (1976) Int. J. Cancer 17, 
565-577. 
Collins, S.J., Gallo, R.C. and Gallagher, R.E. (1977) Nature 
270, 347-349. 
‘Tsuchiya, S., Yamabern, M., Yamaguchi, Y., Kobayashi, Y., 
Konno, T. and Tada, K. (1980) Int. .I. Cancer 26, 171-176. 
Lozzio, C. and Lorzio, B.B. (1975) Blood 45, 321-334. 
Martin, P. and Papayannopoulou, T. (1982) Science 216, 
1233-1235. 
Kasukabe, T., Honma, Y., Horumi, M. and Nomura, H. (1990) 
Jpn. J. Cancer Res. 81, 807-812. 
Kasukabe. T., Honma, Y. and Hozumi, M. (1979) Biochim. 
Biophys. Acta 586, 615-623. 
Rowley, P.T., Ohlsson-Wilhelm, B.M., Fartey, B.A. and 
LeBella, S. (1981) Exp. Hematol. 9, 32-37. 
Saitoh, M., Naka, %l. and Hidaka, H. (1986) Biochem. Biophys. 
Res. Commun. 140, 2X0-287. 
Saitoh, M,, lshikawa, T., Matsushima. S., Naka, M. and 
Hidaka, H. (1987) J. Biol. Chem. 262, 7796-7801. 
Hidaka, H., lnagaki, M., Kawamoto, S. and Sasaki, Y. (1084) 
Biochemistry 23, 5036-5041, 
Ito, M., Tanaka, T., Inagaki, M., Nakanishi, K. and Hidaka. H. 
(1986) Biochemistry 2.5. 4179-4184. 
Hidaka, H., Sasaki, I’., Tanaka, T., Endo, T., Ohno, S., Fujii, 
Y. and Nagara. T. (1981) Pro<. Nari. Acad. Sci. USA 78, 
1354-4357. 
Pa~~ayannopoulou, T., Nakamoto, B., Yokochi, T., Chait, A. 
and Kannagi, R. (1983) Blood 62, 832-845. 
Nishikawa, M., Hidaka, H. and Adelstein, R.S. (1983) J. Uiol. 
Chem. 258, 14069-14072. 
Honma, Y. Okabe-Kado, J., Hozumi, M., Suds, T. and Miura, 
Y. (1991) lnt. J. Hematol. 54 (Suppt. l), 125. (Jpn. Abstr.) 
Tamaoki, T., Nornoto, I-l., Takasaki, I., Kato, Y., Morimoto, 
M. and Tomita, F. (1956) Biochem. Biophys. Res. Commun. 
135, 397-402. 
Hannun, Y .A., Loomis, C.R., Merrill, A.H., Jr. and Bell, R.M. 
(1986) f. Biol. C’hem. 261, 12601-12609. 
Ina_gaki, M., Kawamoto, S., ltoh, H., Saitoh. M., Hagiwara, 
M., Takahashi, J. and Hidaka, H. (1985) Mol. Pharmacol. 29, 
577-581. 
177 
